Relay Therapeutics (RLAY) President Bergstrom Buys $385K of Stock

Donald Bergstrom, President of Research and Development at RLAY, made a notable move by purchasing 93,456 shares of the company on June 22, 2026. This transaction was valued at approximately $385,038.72, with an average purchase price of $4.12 per share. The transaction was not part of a pre-planned trading program.

Insider Buying and Selling at Relay Therapeutics, Inc.

On the same day, Thomas Catinazzo, RLAY's Chief Financial Officer, also engaged in stock transactions. Catinazzo bought 169,446 shares without a pre-set plan. Meanwhile, he sold 187,163 shares at an average price of $16.97 under a pre-planned trading program. Bergstrom also sold 93,456 shares at $16.94 in a planned transaction.

Other Institutional Activity in RLAY

Institutional investors have shown varied interest in RLAY. SB Investment Advisers held steady with 27,904,963 shares valued at about $277.65 million. Commodore Capital also maintained its position with 17,000,000 shares worth around $169.15 million. Casdin Capital increased its stake by 1,415,000 shares, now holding 14,418,574 shares valued at approximately $143.46 million, marking a 10.9% increase. BlackRock trimmed its holdings by 253,203 shares, resulting in a 1.9% decrease to 12,975,299 shares worth roughly $129.10 million. Perceptive Advisors notably expanded its position by 7,847,896 shares, a substantial 412.3% increase, to 9,751,141 shares valued at approximately $97.02 million.

Relay Therapeutics, Inc. Stock Down 4.4%

Shares of RLAY traded near $18.02 on Thursday. RLAY has been receiving attention from investors and analysts alike, with its stock price reflecting ongoing interest. Institutional investors hold significant stakes, indicating their confidence in the company's potential.

Analysts Set New Price Targets

Analysts remain optimistic about RLAY's future. On May 26, 2026, both Guggenheim and HC Wainwright & Co. maintained their buy ratings, setting price targets at $26 and $28, respectively. Barclays and Citizens also reiterated their buy ratings on May 20, with targets of $27 and $21. Earlier, on April 28 and 29, HC Wainwright & Co. and Goldman Sachs upheld their buy ratings with targets of $25 and $22.

Bottom Line

Donald Bergstrom's recent purchase reflects his confidence in RLAY's prospects. Institutional investors and analysts are also showing strong support, with multiple buy ratings and favorable price targets. However, it's important to remember that insider transactions and institutional holdings can change over time, and these filings provide a snapshot of past activity.